세계의 피부 치료제 시장(2023-2030년)

Market Overview

The Global Dermatology Drugs Market size was worth US$ 18,684.8 million in 2022 and is estimated to reach US$ 40,830.9 million by 2030, growing at a CAGR of 10.5% during the forecast period (2023-2030).

Dermatology can help people overcome acne, inspect skin blemishes, get skin cancer screenings, treat eczema and psoriasis, and much more. When it comes to things happening under the surface, your skin can tell you everything.

Market Dynamics

Launch of Therapeutically Effective Drugs

The frequent introduction of new and customer-focused goods is expected to have a greater impact on the global dermatological medicines business. For example, Eli Lilly's psoriasis treatment has received approval from India's DCGI, allowing the business to access the Indian dermatological market. Marketing methods such as website launches, TV and social media commercials promoting campaign awareness, and others will also aid in the market's development over the forecast period.

Rising Prices Of Dermatology Drugs

The increasing costs associated with these medications hinder market expansion. Many market participants make large investments in the development of new pharmaceuticals in order to speed up the recovery process, which raises the cost. As a result, this issue impedes market expansion because treatment alternatives are not practical for all income groups.

COVID-19 Impact Analysis

COVID-19 has a terrifying effect on dermatological medications. Many current clinical trials for dermatological treatments were interrupted by the pandemic, affecting market growth as many trials were discontinued or postponed due to safety concerns, limited patient visits to clinics, and prioritisation of resources for COVID-19 research. As a result, medication research and clearance schedules have been pushed back.

Also Patient visits to dermatological clinics were reduced as a result of the epidemic, and elective operations were postponed. As a result, some people may have had delayed diagnosis and treatment for dermatological problems. This delay may have an influence on illness management and overall results.

For more details on this report - Request For Sample

Segment Analysis

The global dermatology drugs market is segmented based on Application , Drug class and End user

The Acne Application Segment will be Dominated By Market Players During the Forecast Period.

Acne is expected to grow at a significant CAGR during the forecast period, owing to an increase in the number of market participants offering improved products internationally. Acne prevalence is also increasing, particularly among young people, which is a key factor contributing to the expansion of this category. Furthermore, the availability of a wide selection of acne products at retail pharmacies, as well as the convenience of access, are fueling the development of this market.

Geographical Analysis

North America is The Dominating Region During The Forecast Period.

Northa america has been dominating region for dermatology drugs market because of the rising incidence of dermatological infections. North America accounted for the majority of the market share of 38.7%. Another key aspect contributing to the region's growth is the presence of big businesses along with new launches. North America also possesses the most recent technology advances in R&D. This, together with increased dermatological product sales, is likely to fuel growth throughout the projection period. Furthermore, Asia Pacific is expected to have the highest CAGR due to increased public knowledge about the care and management of acne and other disorders.

Competitive Landscape

The major global players include: Leo Pharma, Allergan, Amgen Inc. GI Dermatics Sanofi Merck & Co. Pfizer, AbbVie, Bausch Health, and Novartis.

Why Purchase the Report?

• To visualize the global dermatology drugs market segmentation based on the Application, drug class, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global dermatology drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global dermatology drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Application
• 3.2. Snippet by Drug class
• 3.3. Snippet by End user

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Launch of therapeutically effective drugs
  • 4.1.2. Restraints
    • 4.1.2.1. Rising prices of dermatology drugs
  • 4.1.3. Opportunity
    • 4.1.3.1. Rise in elderly population
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Drug Class

• 7.1 Atopic Dermatitis
• 7.2 Psoriasis
• 7.3 Acne
• 7.4 Alopecia
• 7.5 Herpes
• 7.6 Rosacea

8. By Drug Class

• 8.1. Anti-Infectives
• 8.2. Anti-Acne
• 8.3. Calcineurin Inhibitors
• 8.4. Retinoids
• 8.5. Corticosteroids
• 8.6. Other Drug classes

9. By End user

• 9.1. Hospitals
• 9.2. Dermatology Clinics
• 9.3. Cosmetic Centers
• 9.4 Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Leo Pharma
• 12.2. Allergan Inc.
• 12.3. Amgen Inc.
• 12.4. GI Dermatics
• 12.5. Sanofi
• 12.6. Merck & Co.
• 12.7. Pfizer
• 12.8. AbbVie
• 12.9. Bausch Health
• 12.10. Novartis

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us